C4 Therapeutics Inc (CCCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 35,584 | 20,756 | 31,096 | 45,785 | 33,195 |
| Gross Profit | 35,584 | 20,756 | 31,096 | 45,785 | 33,195 |
| Operating Expenses | 155,198 | 159,787 | 160,630 | 127,919 | 93,644 |
| Operating Income | -119,614 | -139,031 | -129,534 | -82,134 | -60,449 |
| Interest Expense | 0 | 1,373 | 2,216 | 1,758 | 836 |
| Other Income | 14,429 | 9,191 | 3,575 | 0 | -5,676 |
| Pre-tax Income | -105,185 | -131,213 | -128,175 | -83,892 | -66,961 |
| Income Tax | 131 | 1,280 | N/A | N/A | -626 |
| Net Income Continuous | -105,316 | -132,493 | -128,175 | -83,892 | -66,335 |
| Net Income | $-105,316 | $-132,493 | $-128,175 | $-83,892 | $-66,335 |
| EPS Basic Total Ops | -1.52 | -2.67 | -2.62 | -1.82 | -5.83 |
| EPS Basic Continuous Ops | -1.52 | -2.67 | -2.62 | -1.82 | -5.83 |
| EPS Diluted Total Ops | -1.52 | -2.67 | -2.62 | -1.82 | -5.83 |
| EPS Diluted Continuous Ops | -1.52 | -2.67 | -2.62 | -1.82 | -5.83 |
| EPS Diluted Before Non-Recurring Items | -1.52 | -2.67 | -2.62 | -1.82 | -5.83 |
| EBITDA(a) | $-123,192 | $-140,530 | $-126,431 | $-78,044 | $-58,518 |